BBLG VS LLY Stock Comparison

PerformanceTechnicalsEarningsProfitVolatilityAnalyst Price TargetsDividend
PerformanceTechnicalsEarningsProfitVolatilityAnalyst Price TargetsDividend

Performance

BBLG
10/100

BBLG returned -94.35% in the last 12 months. Based on SPY's performance of 9.73%, its performance is below average giving it a score of 10 of 100.

LLY
100/100

LLY returned 68.15% in the last 12 months. Based on SPY's performance of 13.09%, its performance is above average giving it a score of 100 of 100.

Technicals

BBLG
14/100

BBLG receives a 14 of 100 based on 14 indicators. 2 are bullish, 12 are bearish.

LLY
57/100

LLY receives a 57 of 100 based on 14 indicators. 7 are bullish, 5 are bearish.

Earnings

BBLG
49/100

BBLG has missed earnings 2 times in the last 20 quarters.

LLY
10/100

LLY has missed earnings 7 times in the last 20 quarters.

Profit

BBLG
10/100

Out of the last 20 quarters, BBLG has had 1 profitable quarters and has increased their profits year over year on 1 of them.

LLY
66/100

Out of the last 20 quarters, LLY has had 19 profitable quarters and has increased their profits year over year on 6 of them.

Volatility

BBLG
46/100

BBLG has had a lower than average amount of volatility over the last 12 months giving it a score of 45 of 100.

LLY
53/100

LLY has had a higher than average amount of volatility over the last 12 months giving it a score of 53 of 100.

Analyst Price Targets

BBLG

"Analyst Price Targets" not found for BBLG

LLY
68/100

22 analysts offer 12-month price targets for LLY. Together, they have an average target of 391, the most optimistic target put LLY at 673 within 12-months and the most pessimistic has LLY at 236.

Dividend

BBLG

"Dividend" not found for BBLG

LLY
100/100

LLY's most recent dividend was $0.57 per share, based on a share price of $588.54. It was a payout ratio of 50.90% compared to their total earnings.

All score calculations are broken down here to help you make more informed investing decisions

Bone Biologics Corp Common Stock Summary

Nasdaq / BBLG
Healthcare
Medical - Devices
Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein. The company's NELL-1/DBX is a combination product, which is an osteostimulative recombinant protein that provides target specific control over bone regeneration. It is developing NELL-1/DBX Fusion Device for spinal fusion procedures in skeletally mature patients with degenerative disc disease at one level from L4-S1. The company's platform technology has application in delivering enhanced outcomes in the surgical specialties of spinal, orthopedic, general orthopedic, plastic reconstruction, neurosurgery, interventional radiology, and sports medicine. It has a license agreement with the UCLA Technology Development Group to develop and commercialize NELL-1 for spinal fusion applications. The company was founded in 2004 and is headquartered in Burlington, Massachusetts.

Eli Lilly & Co. Summary

New York Stock Exchange / LLY
Healthcare
Drug Manufacturers - General
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+, HER2- metastatic breast cancer, node positive, and early breast cancer. It offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis. The company offers Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Its Bamlanivimab and etesevimab, and Bebtelovimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. The company has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; Regor Therapeutics Group; Lycia Therapeutics, Inc.; Kumquat Biosciences Inc.; Entos Pharmaceuticals Inc.; and Foghorn Therapeutics Inc. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.